I feel much
about synthetic biology as I do AI: I don’t really understand it from a technical
point of view, but I sure am excited about its potential. Sometimes they even
overlap, as I’ll discuss later. But I’ll start with some recent developments
with bioplastics, a topic I have somehow never really covered.
If you always thought biology was boring, you're not paying enough attention. Credit: Bing Image Creator
Let’s
start with some work at Washington University (St. Louis) involving, of all
things, purple bacteria. In case you didn’t know it – I certainly didn’t –
purple bacteria “are a special group of aquatic microbes renowned for their
adaptability and ability to create useful compounds from simple ingredients,” according
to the press release. The researchers are turning the bacteria into bioplastic
factories.
One study,
led by graduate student Eric Connors, showed that two “obscure” species of purple
bacteria can produce polyhydroxyalkanoates (PHAs), a natural polymer that can
be purified to make plastics. Another
study, led by research lab supervisor Tahina Ranaivoarisoa, took another “well
studied but notoriously stubborn” species of purple bacteria to dramatically
ramp up its production of PHAs, by inserting a gene that helped turn them into “relative
PHA powerhouses.” The researchers are optimistic they could use other bacteria
to produce even higher levels of bioplastics.
Purple bacteria at work. Credit: Joe Angeles/WashU |
The work was
done in the lab of associate professor Aripta Bose, who said: “There’s a huge
global demand for bioplastics. They can be produced without adding CO2
to the atmosphere and are completely biodegradable. These two studies show the
importance of taking multiple approaches to finding new ways to produce this
valuable material.”
“It’s
worth taking a look at bacteria that we haven’t looked at before,” Mr. Conners
said. “We haven’t come close to realizing their potential.” Professor Bose
agrees: “We hope these bioplastics will produce real solutions down the road.”
Meanwhile,
researchers at Korea Advanced Institute of Science and Technology, led by Sang
Yup Lee, have manipulated bacteria to produce polymers that contain “ring-like
structures,” which apparently make the plastics more rigid and thermally
stable. Normally those structures would
be toxic to the bacteria, but the researchers managed to enable E. coli bacteria
to both tolerate and produce them. The
researchers believe that the polymer would be especially useful in biomedical
applications, such as drug delivery.
As with
the Washington University work, this research is not producing output at scale,
but the researchers have good confidence that it can. “If we put more effort
into increasing the yield, then this method might be able to be commercialized
at a larger scale,” says Professor Lee. “We’re working to improve the
efficiency of our production process as well as the recovery process, so that
we can economically purify the polymers we produce.”
Because
the polymer is produced using biological instead of chemical processes, and is
biodegradable, the researchers believe it can be important for the environment.
“I think biomanufacturing will be a key to the success of mitigating climate
change and the global plastic crisis,” says Professor Lee. “We need to
collaborate internationally to promote bio-based manufacturing so that we can
ensure a better environment for our future.”
Environmental
impact is also very much on the minds of researchers at the University of Virginia.
They are working on creating biodegradable bioplastics from food waste. “By
creating cost-effective bioplastics that naturally decompose, we can reduce
plastic pollution on land and in oceans and address significant issues such as
greenhouse gas emissions and economic losses associated with food waste,” said lead
researcher Zhiwu "Drew" Wang.
The
approach is currently still in the pilot project stage.
If all
that isn’t cool enough, our own bodies may become biofactories, such as to deliver
drugs or vaccines. Earlier this year researchers at UT Southwestern reported on “in
situ production and secretion of proteins,” which in this case targeted psoriasis
and two types of cancer.
The
researchers say: “Through this engineering approach, the body can be utilized
as a bioreactor to produce and systemically secrete virtually any encodable
protein that would otherwise be confined to the intracellular space of the
transfected cell, thus opening up new therapeutic opportunities.”
“Instead
of going to the hospital or outpatient clinic frequently for infusions,
this technology may someday allow a patient to receive a treatment at a
pharmacy or even at home once a month, which would be a significant boost to
their quality of life,” said study leader Daniel
Siegwart, Ph.D. Professor Siegwart believes this type of in situ production
could eventually improve health and quality of life for patients with
inflammatory diseases, cancers, clotting disorders, diabetes, and a range of
genetic disorders.
I promised
I’d touch on an example of synthetic biology and AI overlapping. Last year I wrote about how “organoid
intelligence” was a new approach to biocomputing and AI. Earlier this year Swiss
firm FinalSpark launched
its Neuroplatform, which uses 16 human brain organoids as the computing
platform, claiming it was: “The next evolutionary leap for AI.”
“Our
principal goal is artificial intelligence for 100,000 times less energy,”
FinalSpark co-founder Fred Jordan says.
Four clusters of living neurons are connected to electrodes on Neuroplatform/ Credit: FinalSpark
Scientific
America reports
related work at Spain’s National Center for Biotechnology, using cellular computing,
and at the University of the West of England, using – I’m serious! – fungal networks.
“Fungal computing offers several advantages over brain-organoid-based
computing,” Andrew Adamatzky says, “particularly in terms of ethical
simplicity, ease of cultivation, environmental resilience, cost-effectiveness
and integration with existing technologies.”
Bioplastics,
biofactories, biocomputing -- pretty cool stuff all around. I’ll admit I don’t
know where all of this is leading, but I can’t wait to see where it leads.